GSR and hepatocellular carcinoma: Solute carrier family 27 member 5 (SLC27A5, an enzyme that metabolizes fatty acid and bile acid)-deficient HCC cells were insensitive to sorafenib because GSR was overexpressed in an NRF2-dependent manner, whereas sorafenib combined with the selective GSR inhibitor carmustine (BCNU) strongly promoted ferroptosis, elucidating the suppressive effect of SLC27A5 on GSR [188].